Date | Price Target | Rating | Analyst |
---|---|---|---|
7/29/2024 | $48.00 | Buy | Laidlaw |
5/20/2024 | $43.00 | Buy | BTIG Research |
4/29/2024 | $42.00 | Overweight | Piper Sandler |
4/29/2024 | $50.00 | Buy | Guggenheim |
11/14/2023 | $15.00 | Equal-Weight | Morgan Stanley |
11/14/2023 | $20.00 | Outperform | Leerink Partners |
Abivax Provides Operational and Key Program Update Phase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-
PARIS, France, June 4, 2024 – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, held its ordinary and extraordinary general meeting of shareholders on May 30, 2024 (the "General Meeting"), which was chaired by Mr. Marc de Garidel, CEO and Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board and, in particular, the financial statements for the 2023 financial year, the compensation poli
Sofinnova Investments, a healthcare investment firm, announced today the appointment of Troy Ignelzi to the investment team as an Executive Advisor. In this role, he will be advising Sofinnova's portfolio companies on corporate and financial strategy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240312683597/en/Troy Ignelzi, Executive Advisor, Sofinnova Investments (Photo: Business Wire) Mr. Ignelzi brings to Sofinnova over two decades of financial leadership experience in the biotech and pharmaceuticals sectors. He is currently Chief Financial Officer at Rapport Therapeutics, a clinical-stage biotechnology company leveraging
Abivax Announces First Patient Enrolled in ENHANCE-CD, the Phase 2b Trial of Obefazimod in Crohn's Disease PARIS, France, October 3, 2024 – 10:00 p.m. CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the first patient was enrolled in its Phase 2b ENHANCE-CD (NCT06456593) trial evaluating obefazimod in patients with Crohn's disease (CD). The multicenter, double-blind, randomized, placebo-controlled trial will evaluate the efficacy and safety
Abivax Reports Positive Interim Efficacy and Safety Analysis of Once-Daily 25mg Obefazimod in Moderate to Severe Ulcerative Colitis Patients After 2-Years of Open-Label Maintenance Patients treated with a de-escalated dose of 25 mg of obefazimod once daily demonstrated maintenance of clinical remission at weeks 48 and 96Efficacy and safety demonstrated out to six years of treatment The treatment was well-tolerated, with a safety profile consistent with previous studies and no new safety signals detected PARIS, France, October 3, 2024, 8:30 a.m. CEST – Abivax SA ((Euronext Paris &, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing ther
Abivax to Present Three Abstracts for Obefazimod in Ulcerative Colitis at the UEG Week 2024 Professor Bruce E. Sands, MD to present oral presentation of Phase 2b, open-label, maintenance efficacy and safety data at weeks 48 and 96 among week 8 induction non-responders in obefazimod-treated patients with moderately to severely active ulcerative colitis (UC)Two moderated poster presentations highlighting corticosteroid-free efficacy and safety data of obefazimod at weeks 48 and 96 of an open-label maintenance trial, as well as the impact of obefazimod induction therapy on combined histologic and endoscopic outcomes at week 8 in patients with UC PARIS, France, September 26, 2024 – 08:30 a.m.
Abivax Provides Operational and Key Program UpdatePhase 3 ABTECT Trial evaluating obefazimod in moderately to severely active ulcerative colitis (UC) on track to complete enrollment in early Q1 2025Top-line results from the ABTECT 8-week induction trial expected early Q2 2025, with 44-week maintenance data on pace to read out in Q1 2026; timing assumptions for New Drug Application (NDA) submission remain unchangedContinued progress on pre-clinical combination therapy programSylvie Grégoire named Chair of Abivax's Board of Directors; Dr. Fabio Cataldi named Chief Medical Officer and Dr. David Zhang named Chief Strategy OfficerCash position allows for runway into Q4 2025 through ABTECT 8-week
U.S. stock futures were mixed this morning, with the Dow futures falling around 50 points on Monday. Shares of AMC Networks Inc. (NASDAQ:AMCX) fell sharply in today's pre-market trading after the company announced a private offering of $125 million of convertible senior notes. AMC Networks shares dipped 9.4% to $14.24 in pre-market trading. Here are some big stocks recording losses in today's pre-market trading session. Evotec SE (NYSE:EVO) shares fell 7.7% to $4.20 in pre-market trading. Absci Corporation (NASDAQ:ABSI) declined 5.8% to $3.75 in pre-market trading after declining around 9% on Friday. Humacyte, Inc. (NASDAQ:HUMA) fell 5.7% to $6.65 in pre-market trading.
BTIG analyst Julian Harrison initiates coverage on Abivax (NASDAQ:ABVX) with a Buy rating and announces Price Target of $43.
6-K - Abivax S.A. (0001956827) (Filer)
6-K - Abivax S.A. (0001956827) (Filer)
6-K - Abivax S.A. (0001956827) (Filer)
SC 13G - Abivax S.A. (0001956827) (Subject)
Laidlaw initiated coverage of Abivax SA with a rating of Buy and set a new price target of $48.00
BTIG Research initiated coverage of Abivax SA with a rating of Buy and set a new price target of $43.00
Piper Sandler initiated coverage of Abivax SA with a rating of Overweight and set a new price target of $42.00